Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes.
Matthews
David R
DR
Professor of Diabetes Medicine, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, OX3 7LJ, UK. david.matthews@ocdem.ox.ac.uk
Tsapas
Apostolos
A
D001786:Blood Glucose / Q000187:drug effects*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000266:history / Q000378:metabolism / Q000517:prevention & control*; D002986:Clinical Trials as Topic / Q000266:history / Q000379:methods; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000266:history / Q000378:metabolism; D019317:Evidence-Based Medicine; D006442:Glycated Hemoglobin / Q000378:metabolism*; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007004:Hypoglycemic Agents / Q000266:history / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D012107:Research Design; D016896:Treatment Outcome
D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; C517652:hemoglobin A1c protein, human